GEA opens factory in India
Vadodara, Gujarat factory provides local build of processing equipment
Until now GEA Pharma Systems, the technology leader in pharmaceutical processing, has manufactured outside India, mainly in Europe. The new factory will offer strategic low-cost manufacturing, allowing the company to provide European-quality processing equipment at prices that are affordable in the growing Indian market.
‘India is a high-growth market that’s very price-sensitive and susceptible to technology,’ said Navin Lakhanpaul, regional manager for GEA Pharma Systems in Vadodara. ‘This low-cost manufacturing base will allow us to provide the high-end, European quality products our Indian customers need at prices that are appropriate to the local market.’ He added that the local manufacture will also help the company be more reactive to local market demands.
The factory will employ local staff and peripheral equipment, such as control systems, will also be sourced locally, providing an additional boost to local suppliers. ‘In most projects, much of the project value is in peripheral equipment. It’s also essential for us to keep the technical know-how close at hand to help us maintain the efficient after-sales service our customers expect,’ said Navin.
The effects of low-cost manufacturing, locally-sourced peripheral equipment and reduced transportation costs can often reduce the equipment price significantly when compared with equipment bought from Europe.
Navin also explained that the high quality approach satisfied the demand for all pharmaceutical equipment produced in India to meet international quality standards. ‘Not only do our Indian customers want to supply the local market with high-quality products they also want the facilities necessary to sell into Europe and offer manufacturing services to European customers. Our equipment provides the necessary quality, efficiency and environmental control to allow them to do so.’
Frans Maas, GEA Pharma Systems’ division director for sales and marketing, commented that the new facility was critical to the organisation’s long-term plans. ‘The factory in Vadodora is an important development for our company and part of our strategy for sustainable supply,’ he explained. The opening of the factory, for example, follows soon after GEA’s announcement of two agency agreements with ACE Technologies of Mumbai, for the distribution of MODUL tablet presses from GEA Courtoy and pharmaceutical freeze drying technology from GEA Lyophil throughout India.
The factory has been built adjacent to the company’s existing office building which was opened in 2007.
You may also like
Trending Articles
Upcoming event
You may also like
Manufacturing
Nulogy launches Supplier Compliance Management to build stronger, more resilient supplier networks
Nulogy, a leading provider of manufacturing operations software, announced the launch of Nulogy Supplier Compliance Management, a solution designed to centralise and automate supplier compliance for procurement, supply chain, and quality assurance teams in manufacturing, food & beverage, pharmaceuticals, and
other highly regulated industries
Manufacturing
AQUARIA - enhancing drying performance while reducing consumption
AQUARIA stands out within the diverse range of parts washers for the pharmaceutical industry that have been developed by IMA over the last two decades. Designed to ensure maximum performance in cleaning and validation with high efficiency, AQUARIA is renowned for its reduced consumption of energy, water, detergents and compressed air. These qualities match the pharmaceutical industry’s current attention to environmental issues and prove how IMA is actively supporting sustainability across a wide spectrum of processes, where its solutions represent a respected benchmark
Manufacturing
Clariant opens first US pharmaceutical-grade PEG excipient manufacturing site in Texas
Clariant has expanded its Clear Lake facility in Texas to produce GMP-compliant pharmaceutical-grade polyethylene glycol excipients, marking its first US-based manufacturing site for the products and strengthening supply chain resilience for North American and Latin American pharma customers